// App-Quantinova.ai

5076 : Evaluation of the CNS penetration of a next generation PARP inhibitor, AZD9574, in cynomolgus monkey using positron emission tomography

Researchers

Presenter

  • Andy Pike

Principal Investigators

  • Amber Balazs

  • Zsolt Cselényi

  • Sébastien L. Degorce

  • Avipsa Ghosh

  • Sudhir M. Hande

  • Jeffrey Johannes

  • Peter Johnström

  • Martin J. Packer

  • Magnus Schou

  • XiaoLan Zheng

Medical Centers

  • Astra Zeneca, Cambridge, United Kingdom

  • AstraZeneca, Waltham, MA

  • AstraZeneca, Stockholm, Sweden

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain cancer

Biomarkers

  • Poly(ADP-Ribose) Polymerase 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved